The Europe Microbial Fermentation Technology Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).
Due to the microbial biopharmaceutical industry's explosive rise over the last few years, the microbial fermentation technology market has seen an increase in demand. The advantages of utilizing microbial organisms in production processes over mammalian cell culture, such as faster development times, higher expression levels, and lower medium costs, have greatly influenced this interest. In general, microbial fermentation technology delivers cheaper production costs, higher yields, quicker development, improved scalability, decreased fluctuation between batches, and faster yields.
The industry is also expected to rise with the demand for microbiological contract manufacturing services. Currently, more than 115 business owners are actively providing microbial fermentation services. Due to the presence of reputable companies like Lonza, AbbVie Contract Manufacturing, and others, the industry is, therefore, very fragmented. The presence of so many service providers is anticipated to fuel market expansion in the upcoming years.
The European Medicines Agency, for instance, has developed a comprehensive list of accessibility guidelines and opportunities for CDMO participation during the development stage of a medical product (EMA). The EMA gives drug researchers several opportunities for early consultation and discussion before suggesting a marketing authorization application. This is intended to offer regulatory and scientific help for developing applications and ensuring a smooth validation and assessment process. In addition, government funding and growing CVD awareness in the region are driving the market for microbial fermentation technology to expand.
The Germany market dominated the Europe Microbial Fermentation Technology Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,249.6 million by 2028. The UK market is anticipated to grow at a CAGR of 4.3% during (2022 - 2028). Additionally, The France market would experience a CAGR of 6% during (2022 - 2028).
Based on Application, the market is segmented into Antibiotics, Recombinant Proteins, Enzymes, Monoclonal Antibodies, Probiotics Supplements, Vaccines, Biosimilars, Small Molecules and Others. Based on End User, the market is segmented into CMOs & CDMOs, Bio-Pharmaceutical Companies, Contract Research Organizations (CROs) and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Microbial Fermentation Technology Market will Hit $42.4 Billion by 2028, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biocon Limited, BioVectra Inc. (H.I.G. Capital, LLC), Danone S.A., F. Hoffmann-La Roche Ltd., Koninklijke DSM N.V., Lonza Group AG, Novozymes A/S (Novo Holdings A/S), Corbion N.V., and Bangalore Biotech Labs Pvt. Ltd. (BiOZEEN).
By Application
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
